DiaMedica schedules Oct. 23 webinar to present interim Phase 2 early-onset fetal growth restriction data for DM199
Bitget2026/09/30 12:30- DiaMedica Therapeutics set an Oct. 23, 2026 virtual KOL webinar on DM199 in early-onset fetal growth restriction.
- Early interim topline findings from the first Phase 2 cohort were already generated, with safety and initial trial observations to be presented.
- Enrollment finished for the first cohort; dosing has started in the second cohort, marking the first use of DM199 in early-onset FGR.
- Management framed the initial readout as supporting further evaluation of DM199 as a potential treatment option in FGR.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ido Ben-Natan: Frequent on-chain security incidents, AI agents will increase risks
BTC rebounds and breaks through 83,000 USDT, with a 24-hour decrease of 1%
Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly
The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Crypto prices
More
